Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

 


Get this Report



PayPal Verified Vendor

Rating

4.8 Star Rating for report Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 509
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8845IDBMultiple Sclerosis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8832IDBSmoking Addiction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8798IDBLennox-Gastaut Syndrome - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8805IDBHuntington Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8810IDBEncephalopathy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-30 

Report: Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 7
Amyotrophic Lateral Sclerosis Overview 8
Therapeutics Development 9
Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 11
Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 20
Amyotrophic Lateral Sclerosis - Pipeline Products Glance 22
Amyotrophic Lateral Sclerosis - Products under Development by Companies 26
Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 35
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 38
Amyotrophic Lateral Sclerosis - Therapeutics Assessment 128
Drug Profiles 150
Amyotrophic Lateral Sclerosis - Discontinued Products 474
Amyotrophic Lateral Sclerosis - Product Development Milestones 476
Appendix 488
 

List of Tables

List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 32
Number of Products under Development by Companies, H2 2016 (Contd..1) 33
Number of Products under Development by Companies, H2 2016 (Contd..2) 34
Number of Products under Development by Companies, H2 2016 (Contd..3) 35
Number of Products under Development by Companies, H2 2016 (Contd..4) 36
Number of Products under Development by Companies, H2 2016 (Contd..5) 37
Number of Products under Development by Companies, H2 2016 (Contd..6) 38
Number of Products under Development by Companies, H2 2016 (Contd..7) 39
Number of Products under Investigation by Universities/Institutes, H2 2016 40
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 41
Comparative Analysis by Late Stage Development, H2 2016 42
Comparative Analysis by Clinical Stage Development, H2 2016 43
Comparative Analysis by Early Stage Development, H2 2016 44
Comparative Analysis by Unknown Stage Development, H2 2016 45
Products under Development by Companies, H2 2016 46
Products under Development by Companies, H2 2016 (Contd..1) 47
Products under Development by Companies, H2 2016 (Contd..2) 48
Products under Development by Companies, H2 2016 (Contd..3) 49
Products under Development by Companies, H2 2016 (Contd..4) 50
Products under Development by Companies, H2 2016 (Contd..5) 51
Products under Development by Companies, H2 2016 (Contd..6) 52
Products under Development by Companies, H2 2016 (Contd..7) 53
Products under Development by Companies, H2 2016 (Contd..8) 54
Products under Investigation by Universities/Institutes, H2 2016 55
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 56
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 57
Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016 58
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2016 59
Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics Inc, H2 2016 60
Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016 61
Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H2 2016 62
Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H2 2016 63
Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H2 2016 64
Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H2 2016 65
Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H2 2016 66
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2016 67
Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H2 2016 68
Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 69
Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016 70
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 71
Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2016 72
Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 73
Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corp, H2 2016 74
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H2 2016 75
Amyotrophic Lateral Sclerosis - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 76
Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H2 2016 77
Amyotrophic Lateral Sclerosis - Pipeline by Curatis Pharma GmbH, H2 2016 78
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H2 2016 79
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H2 2016 80
Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals Inc, H2 2016 81
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H2 2016 82
Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H2 2016 83
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2016 84
Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 85
Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma, Inc., H2 2016 86
Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc, H2 2016 87
Amyotrophic Lateral Sclerosis - Pipeline by Gemac, H2 2016 88
Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H2 2016 89
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 90
Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2016 91
Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H2 2016 92
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H2 2016 93
Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H2 2016 94
Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H2 2016 95
Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H2 2016 96
Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H2 2016 97
Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 98
Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H2 2016 99
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 100
Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H2 2016 101
Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016 102
Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H2 2016 103
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H2 2016 104
Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 105
Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 106
Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H2 2016 107
Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016 108
Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H2 2016 109
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2016 110
Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H2 2016 111
Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H2 2016 112
Amyotrophic Lateral Sclerosis - Pipeline by MeiraGTx Limited, H2 2016 113
Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H2 2016 114
Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics Inc, H2 2016 115
Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H2 2016 116
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 117
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H2 2016 118
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 119
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2016 120
Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016 121
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2016 122
Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H2 2016 123
Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2016 124
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SA, H2 2016 125
Amyotrophic Lateral Sclerosis - Pipeline by Plex Pharmaceuticals Inc, H2 2016 126
Amyotrophic Lateral Sclerosis - Pipeline by Prevacus Inc, H2 2016 127
Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H2 2016 128
Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc, H2 2016 129
Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016 130
Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016 131
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2016 132
Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2016 133
Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 134
Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences LLC, H2 2016 135
Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 136
Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed SL, H2 2016 137
Amyotrophic Lateral Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016 138
Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 139
Amyotrophic Lateral Sclerosis - Pipeline by Thera Neuropharma Inc, H2 2016 140
Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H2 2016 141
Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016 142
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co Ltd, H2 2016 143
Amyotrophic Lateral Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 144
Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics Inc, H2 2016 145
Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd, H2 2016 146
Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016 147
Assessment by Monotherapy Products, H2 2016 148
Assessment by Combination Products, H2 2016 149
Number of Products by Stage and Target, H2 2016 151
Number of Products by Stage and Mechanism of Action, H2 2016 159
Number of Products by Stage and Route of Administration, H2 2016 167
Number of Products by Stage and Molecule Type, H2 2016 169
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2016 483
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H2 2016 484
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H2 2016 485
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H2 2016 486
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H2 2016 487
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H2 2016 488
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H2 2016 489
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H2 2016 490
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H2 2016 491
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..9), H2 2016 492
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..10), H2 2016 493
Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2016 494
Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H2 2016 495
 

List of Figures

List of Figures
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016 29
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 40
Comparative Analysis by Late Stage Development, H2 2016 42
Comparative Analysis by Clinical Stage Development, H2 2016 43
Comparative Analysis by Early Stage Products, H2 2016 44
Assessment by Monotherapy Products, H2 2016 148
Assessment by Combination Products, H2 2016 149
Number of Products by Top 10 Targets, H2 2016 150
Number of Products by Stage and Top 10 Targets, H2 2016 150
Number of Products by Top 10 Mechanism of Actions, H2 2016 158
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 158
Number of Products by Top 10 Routes of Administration, H2 2016 166
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 166
Number of Products by Top 10 Molecule Types, H2 2016 168
Number of Products by Stage and Top 10 Molecule Types, H2 2016 168
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively.Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Central Nervous System 
Pages: 509 

Companies Featured

2-BBB Medicines BV AB Science SA Aestus Therapeutics Inc Anavex Life Sciences Corp Angion Biomedica Corp Apodemus AB Apogenix GmbH Apotex Inc ArmaGen Inc BioCrea GmbH Biogen Inc Biohaven Pharmaceutical Holding Company Limited BioHealthonomics Inc BrainStorm Cell Therapeutics Inc Calico LLC Catabasis Pharmaceuticals Inc Cellceutix Corp Chronos Therapeutics Ltd ContraVir Pharmaceuticals Inc Corcept Therapeutics Inc Curatis Pharma GmbH Cytokinetics Inc Daval International Ltd Edison Pharmaceuticals Inc Eisai Co Ltd Ensemble Therapeutics Corp Evotec AG F. Hoffmann-La Roche Ltd Flex Pharma, Inc. FPRT Bio Inc Gemac Genentech Inc Genervon Biopharmaceuticals LLC GeNeuro SA GenKyoTex SA Glialogix Inc Grifols SA Herantis Pharma Plc ImStar Therapeutics Inc. InFlectis BioScience Ionis Pharmaceuticals Inc Italfarmaco SpA Jeil Pharmaceutical Co Ltd Kadimastem Ltd Karyopharm Therapeutics Inc KineMed Inc Kringle Pharma Inc Kyorin Pharmaceutical Co Ltd Kyowa Hakko Kirin Co Ltd Lascco SA Lead Discovery Center GmbH M's Science Corp Maas Biolab Mallinckrodt Plc MedDay SA MeiraGTx Limited miCure Therapeutics Ltd. miRagen Therapeutics Inc MitoDys Therapeutics Limited Mitsubishi Tanabe Pharma Corp Neuralstem Inc Neuraltus Pharmaceuticals Inc Neurimmune Holding AG Neurotec Pharma SL Neurotune AG Orion Oyj Orphazyme ApS Pharnext SA Plex Pharmaceuticals Inc Prevacus Inc Primary Peptides, Inc. ProMIS Neurosciences Inc Q Therapeutics Inc ReceptoPharm Inc Regenesance BV reMYND NV Saneron CCEL Therapeutics Inc SciFluor Life Sciences LLC SK Biopharmaceuticals Co Ltd Spherium Biomed SL Symic Biomedical Inc Teva Pharmaceutical Industries Ltd Thera Neuropharma Inc Treeway BV Valeant Pharmaceuticals International Inc ViroMed Co Ltd VivaCell Biotechnology Espana SL Voyager Therapeutics Inc WAVE Life Sciences Ltd Yooyoung Pharmaceutical Co Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8845IDBMultiple Sclerosis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8832IDBSmoking Addiction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8798IDBLennox-Gastaut Syndrome - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8805IDBHuntington Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8810IDBEncephalopathy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

Report 05IB-GMDHC8730IDB has a rating of 95.9 percent
Figure of merit assessment for report 05IB-GMDHC8730IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7188

Taxonomy Location

The taxonomy on the left shows the ancestors of the Central Nervous System node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Central Nervous System

Central Nervous System

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8730IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [3.62059s]

--